RhumbLine Advisers’s Avalo Therapeutics AVTX Stock Holding History

RhumbLine Advisers’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$985K	Buy	+53,290	New	+$842K	﹤0.01%	2323
2022 Q2	–	Sell	-17	Closed	-$36K	–	3104
2022 Q1	$36K	Buy	17 +1	+6%	+$2.51K	﹤0.01%	2990
2021 Q4	$80K	Hold	16	–	–	﹤0.01%	2960
2021 Q3	$103K	Hold	16	–	–	﹤0.01%	2992
2021 Q2	$151K	Buy	16 +7	+78%	+$58.6K	﹤0.01%	2944
2021 Q1	$77K	Hold	9	–	–	﹤0.01%	2957
2020 Q4	$66K	Buy	9 +2	+29%	+$13.9K	﹤0.01%	3005
2020 Q3	$49K	Sell	7 -1	-13%	-$7.52K	﹤0.01%	2950
2020 Q2	$60K	Buy	8 +2	+33%	+$14.5K	﹤0.01%	3020
2020 Q1	$43K	Hold	6	–	–	﹤0.01%	2872
2019 Q4	$94K	Hold	6	–	–	﹤0.01%	2877
2019 Q3	$57K	Hold	6	–	–	﹤0.01%	2919
2019 Q2	$94K	Buy	+6	New	+$90.9K	﹤0.01%	2934

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RhumbLine Advisers's AVTX Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 53,290 shares worth $985K. The stake represents ﹤0.01% of the portfolio and ranks #2323 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in AVTX as recently as Q1 2022.

RhumbLine Advisers first reported a position in AVTX in Q2 2019 and has held it in 13 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

RhumbLine Advisers held 53,290 shares of Avalo Therapeutics worth $985K as of Q2 2026.
Avalo Therapeutics was a new RhumbLine Advisers position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2323 holding.
RhumbLine Advisers first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 13 quarters since.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.